中国生物制药净利增长31.4%，创新药成产业升级核心引擎

Core Viewpoint - The company has demonstrated significant growth in revenue and net profit for 2025, with a notable increase in innovative product revenue, indicating a strategic shift towards becoming a platform-based innovative pharmaceutical enterprise [1][3]. Financial Performance - In 2025, the company achieved a total revenue of 31.83 billion yuan, representing a year-on-year growth of 10.3%, and an adjusted net profit of 4.54 billion yuan, up 31.4% year-on-year [1]. - Innovative product revenue surpassed 15.22 billion yuan, accounting for nearly 48% of total revenue, with a year-on-year growth of 26.2% [1]. Product Development - The company expanded its innovative product matrix in 2025, with four new products approved by NMPA, including significant drugs for cancer treatment [2]. - The core product, Anlotinib, received approvals for three new first-line indications, bringing the total to ten, solidifying its market position as a leading anti-angiogenic drug [2]. Research and Development - R&D investment reached 5.87 billion yuan in 2025, a year-on-year increase of over 15%, constituting 18.4% of total revenue [4]. - The company has established ten core technology platforms and a professional R&D team of over 2,900 members, advancing more than 130 clinical studies [4]. Strategic Acquisitions - In early 2026, the company acquired the domestic siRNA innovator Hejia for 1.2 billion yuan, enhancing its capabilities in the small nucleic acid field [4][5]. - The company also entered a global licensing agreement with Sanofi for the innovative drug Roflumilast, valued at over 1.53 billion USD, marking a significant milestone in its international strategy [5]. Market Position and Future Outlook - The company is positioned to leverage its innovative pipeline for future growth, with over 20 innovative drugs or new indications expected to be launched between 2026 and 2028 [9]. - The recent government emphasis on biopharmaceuticals as a pillar industry is expected to enhance the market potential for innovative drugs, with a notable increase in outbound licensing deals [6][7]. Industry Trends - The biopharmaceutical sector is undergoing a structural adjustment, transitioning from capital-driven expansion to a focus on clinical value and quality improvement [7]. - The total value of outbound licensing deals for Chinese innovative drugs reached 135.66 billion USD in 2025, making China the leader in this area [7][8].